Ivermectin treatment for gynecologic cancers-Hope versus hype (2025)

Peer-Reviewed Study · Straughn JM Jr · August 2025

Straughn JM Jr, 2025-08: Editorial by a gynaecologic oncologist arguing that preclinical anticancer signals for repurposed drugs, including ivermectin, have repeatedly failed to produce clinical benefit in randomised trials, and that off-patent drugs lack commercial funding for such trials.

Finally, while preclinical data may suggest anticancer activity, most repurposed agents fail to demonstrate meaningful clinical benefit when evaluated in randomized trials, underscoring the need for robust translational research.

n/a (HTML full text)

Straughn JM Jr, 2025-08: Editorial by a gynaecologic oncologist arguing that preclinical anticancer signals for repurposed drugs, including ivermectin, have repeatedly failed to produce clinical benefit in randomised trials, and that off-patent drugs lack commercial funding for such trials. Study type: editorial (opinion, not primary data). N: n/a. Country: USA (University of Alabama at Birmingham, Division of Gynecologic Oncology). Dose/route/schedule: n/a. Funder/COI: see PMC12399274. Comparator: n/a. Recorded at full strength as a contrary view on the weight of the preclinical record. Study type: other.